InsidersTradesSigma
Follow the Zymeworks BC Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €1.6bn. The latest transaction was disclosed on 14 November 2022 (Levée d'options). Among the most active insiders: Josephson Neil. The full history is openly available.
Analysts rate Zymeworks BC Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$39.33.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
Zymeworks BC Inc. 是一家生物制药公司，专注于开发用于治疗癌症和其他疾病的蛋白质疗法。该公司在纳斯达克上市，股票代码为 ZYME。